BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...

BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the ...

Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.

The German pharmaceutical company BioNTech announced on Friday that it has reached settlements in the US to resolve a ...

German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to resolve separate ...

Pharma majors like BioNTech in Germany and Pfizer in the United States have made profits in billions of dollars in selling ...

BioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine ...

BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.

Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...

Bengaluru: German biotechnology company BioNTech has reached two separate settlement agreements with the U.S. National ...

The ADR's fall snapped a three-day winning streak.